Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines
- PMID: 34914046
- DOI: 10.1007/978-1-0716-1884-4_7
Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines
Abstract
Coronaviruses are causative agents of different zoonosis including SARS, MERS, or COVID-19 in humans. The high transmission rate of coronaviruses, the time-consuming development of efficient anti-infectives and vaccines, the possible evolutionary adaptation of the virus to conventional vaccines, and the challenge to cover broad human population worldwide are the major reasons that made it challenging to avoid coronaviruses outbreaks. Although, a plethora of different approaches are being followed to design and develop vaccines against coronaviruses, most of them target subunits, full-length single, or only a very limited number of proteins. Vaccine targeting multiple proteins or even the entire proteome of the coronavirus is yet to come. In the present chapter, we will be discussing multi-epitope vaccine (MEV) and multi-patch vaccine (MPV) approaches to design and develop efficient and sustainably successful strategies against coronaviruses. MEV and MPV utilize highly conserved, potentially immunogenic epitopes and antigenic patches, respectively, and hence they have the potential to target large number of coronavirus proteins or even its entire proteome, allowing us to combat the challenge of its evolutionary adaptation. In addition, the large number of human leukocyte antigen (HLA) alleles targeted by the chosen specific epitopes enables MEV and MPV to cover broader global population.
Keywords: Ag-Patch (antigenic patch); COVID-19; Coronavirus; Epitopes; MERSSARS; Multi-epitope vaccine; Multi-patch vaccine; Reverse epitomics; SARS-CoV-2.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
References
Declaration: Patents filed: IN202011037585, IN202011037939, PCT/IN2021/050841.References
-
- Ye Z-W, Yuan S, Yuen K-S et al (2020) Zoonotic origins of human coronaviruses. Int J Biol Sci 16:1686–1697. https://doi.org/10.7150/ijbs.45472 - DOI - PubMed - PMC
-
- Ksiazek TG, Erdman D, Goldsmith CS et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:1953–1966. https://doi.org/10.1056/nejmoa030781 - DOI - PubMed
-
- Kim J II, Kim YJ, Lemey P et al (2016) The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination. Sci Rep 6:18825. https://doi.org/10.1038/srep18825 - DOI - PubMed - PMC
-
- Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 323:1239–1242. https://doi.org/10.1001/jama.2020.2648 - DOI - PubMed
-
- Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous